203 related articles for article (PubMed ID: 29615338)
21. Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing.
Wong SQ; Li J; Tan AY; Vedururu R; Pang JM; Do H; Ellul J; Doig K; Bell A; MacArthur GA; Fox SB; Thomas DM; Fellowes A; Parisot JP; Dobrovic A;
BMC Med Genomics; 2014 May; 7():23. PubMed ID: 24885028
[TBL] [Abstract][Full Text] [Related]
22. Quality metrics for enhanced performance of an NGS panel using single-vial amplification technology.
Barua S; Hsiao S; Clancy E; Freeman C; Mansukhani M; Fernandes H
J Clin Pathol; 2023 Dec; 77(1):46-53. PubMed ID: 36376073
[TBL] [Abstract][Full Text] [Related]
23. Amplicon-Based Targeted Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Tissue.
Strengman E; Barendrecht-Smouter FAS; de Voijs C; de Vree P; Nijman IJ; de Leng WWJ
Methods Mol Biol; 2019; 1908():1-17. PubMed ID: 30649717
[TBL] [Abstract][Full Text] [Related]
24. Multiplatform comparison of molecular oncology tests performed on cytology specimens and formalin-fixed, paraffin-embedded tissue.
Gailey MP; Stence AA; Jensen CS; Ma D
Cancer Cytopathol; 2015 Jan; 123(1):30-9. PubMed ID: 25186473
[TBL] [Abstract][Full Text] [Related]
25. Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making.
De Paoli-Iseppi R; Johansson PA; Menzies AM; Dias KR; Pupo GM; Kakavand H; Wilmott JS; Mann GJ; Hayward NK; Dinger ME; Long GV; Scolyer RA
Pathology; 2016 Apr; 48(3):261-6. PubMed ID: 27020503
[TBL] [Abstract][Full Text] [Related]
26. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.
Hovelson DH; McDaniel AS; Cani AK; Johnson B; Rhodes K; Williams PD; Bandla S; Bien G; Choppa P; Hyland F; Gottimukkala R; Liu G; Manivannan M; Schageman J; Ballesteros-Villagrana E; Grasso CS; Quist MJ; Yadati V; Amin A; Siddiqui J; Betz BL; Knudsen KE; Cooney KA; Feng FY; Roh MH; Nelson PS; Liu CJ; Beer DG; Wyngaard P; Chinnaiyan AM; Sadis S; Rhodes DR; Tomlins SA
Neoplasia; 2015 Apr; 17(4):385-99. PubMed ID: 25925381
[TBL] [Abstract][Full Text] [Related]
27. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.
Gray PN; Vuong H; Tsai P; Lu HM; Mu W; Hsuan V; Hoo J; Shah S; Uyeda L; Fox S; Patel H; Janicek M; Brown S; Dobrea L; Wagman L; Plimack E; Mehra R; Golemis EA; Bilusic M; Zibelman M; Elliott A
Oncotarget; 2016 Oct; 7(42):68206-68228. PubMed ID: 27626691
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of DNA and RNA quality from archival formalin-fixed paraffin-embedded tissue for next-generation sequencing - Retrospective study in Japanese single institution.
Fujii T; Uchiyama T; Matsuoka M; Myojin T; Sugimoto S; Nitta Y; Okabe F; Sugimoto A; Sekita-Hatakeyama Y; Morita K; Itami H; Hatakeyama K; Ohbayashi C
Pathol Int; 2020 Sep; 70(9):602-611. PubMed ID: 32542983
[TBL] [Abstract][Full Text] [Related]
29. Validation of a next generation sequencing panel for detection of hotspot cancer mutations in a clinical laboratory.
Shahsiah R; DeKoning J; Samie S; Latifzadeh SZ; Kashi ZM
Pathol Res Pract; 2017 Feb; 213(2):98-105. PubMed ID: 28049581
[TBL] [Abstract][Full Text] [Related]
30. Accuracy and reproducibility of somatic point mutation calling in clinical-type targeted sequencing data.
Karimnezhad A; Palidwor GA; Thavorn K; Stewart DJ; Campbell PA; Lo B; Perkins TJ
BMC Med Genomics; 2020 Oct; 13(1):156. PubMed ID: 33059707
[TBL] [Abstract][Full Text] [Related]
31. Clinical next-generation sequencing in patients with non-small cell lung cancer.
Hagemann IS; Devarakonda S; Lockwood CM; Spencer DH; Guebert K; Bredemeyer AJ; Al-Kateb H; Nguyen TT; Duncavage EJ; Cottrell CE; Kulkarni S; Nagarajan R; Seibert K; Baggstrom M; Waqar SN; Pfeifer JD; Morgensztern D; Govindan R
Cancer; 2015 Feb; 121(4):631-9. PubMed ID: 25345567
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous detection of clinically relevant mutations and amplifications for routine cancer pathology.
Hoogstraat M; Hinrichs JW; Besselink NJ; Radersma-van Loon JH; de Voijs CM; Peeters T; Nijman IJ; de Weger RA; Voest EE; Willems SM; Cuppen E; Koudijs MJ
J Mol Diagn; 2015 Jan; 17(1):10-8. PubMed ID: 25445215
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.
Ananda G; Mockus S; Lundquist M; Spotlow V; Simons A; Mitchell T; Stafford G; Philip V; Stearns T; Srivastava A; Barter M; Rowe L; Malcolm J; Bult C; Karuturi RK; Rasmussen K; Hinerfeld D
Exp Mol Pathol; 2015 Feb; 98(1):106-12. PubMed ID: 25562415
[TBL] [Abstract][Full Text] [Related]
34. Pre-clinical validation of a next generation sequencing testing panel.
Lüsebrink J; Pieper M; Tillmann RL; Brockmann M; Schildgen O; Schildgen V
Exp Mol Pathol; 2018 Jun; 104(3):170-174. PubMed ID: 29641993
[TBL] [Abstract][Full Text] [Related]
35. NGS Analysis of Liquid Biopsy (LB) and Formalin-Fixed Paraffin-Embedded (FFPE) Melanoma Samples Using Oncomine™ Pan-Cancer Cell-Free Assay.
Olbryt M; Rajczykowski M; Bal W; Fiszer-Kierzkowska A; Cortez AJ; Mazur M; Suwiński R; Widłak W
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356096
[TBL] [Abstract][Full Text] [Related]
36. Technical in-depth comparison of two massive parallel DNA-sequencing methods for formalin-fixed paraffin-embedded tissue from victims of sudden cardiac death.
Adolfsson E; Qvick A; Gréen H; Kling D; Gunnarsson C; Jonasson J; Gréen A
Forensic Sci Int Genet; 2021 Jul; 53():102522. PubMed ID: 33945952
[TBL] [Abstract][Full Text] [Related]
37. Application of Targeted Next-generation Sequencing, TruSeq Custom Amplicon Assay for Molecular Pathology Diagnostics on Formalin-fixed and Paraffin-embedded Samples.
Csernák E; Molnár J; Tusnády GE; Tóth E
Appl Immunohistochem Mol Morphol; 2017 Aug; 25(7):460-466. PubMed ID: 26808133
[TBL] [Abstract][Full Text] [Related]
38. High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.
Bourgon R; Lu S; Yan Y; Lackner MR; Wang W; Weigman V; Wang D; Guan Y; Ryner L; Koeppen H; Patel R; Hampton GM; Amler LC; Wang Y
Clin Cancer Res; 2014 Apr; 20(8):2080-91. PubMed ID: 24573554
[TBL] [Abstract][Full Text] [Related]
39. Validation of an NGS mutation detection panel for melanoma.
Reiman A; Kikuchi H; Scocchia D; Smith P; Tsang YW; Snead D; Cree IA
BMC Cancer; 2017 Feb; 17(1):150. PubMed ID: 28228113
[TBL] [Abstract][Full Text] [Related]
40. Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.
Wang Y; Liu H; Hou Y; Zhou X; Liang L; Zhang Z; Shi H; Xu S; Hu P; Zheng Z; Liu R; Tang T; Ye F; Liang Z; Bu H
Virchows Arch; 2018 Jun; 472(6):959-968. PubMed ID: 29705968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
